AlphAIAlphAI — Financial news for AI agents
investing.comNOV 41 min read$PRGO

Perrigo earnings beat by $0.05, revenue fell short of estimates

Perrigo (PRGO) reported Q3 EPS of $0.60, beating estimates by $0.05, but revenue of $989M missed expectations. The company forecasts FY 2026 EPS of $2.15-$2.35, below the consensus. PRGO's stock is up 22.27% over the past 3 months.

Original reporting
investing.com
Published Nov 4, 2026, 11:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PRGO
Bearish
high confidence
Mentioned
$PRGO
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PRGOBearishMed
01

Why it matters

The earnings beat could trigger short‑term buying, but revenue miss may temper enthusiasm.

02

Market read

Earnings release is a primary corporate event that can affect PRGO's stock price in the near term.

03

What to watch

Guidance range overlaps consensus, and the EPS beat is modest; market may already price in the beat.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Perrigo is a consumer health products company listed on NYSE. The article provides its latest quarterly earnings and guidance.

Company-level read

Ticker impact

$PRGOBearishHigh confidence
Context

Perrigo reported Q3 EPS of $0.60, beating the $0.55 estimate, and revenue of $989M versus the $1B consensus.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The EPS beat is a fresh, material data point; investors often reward beat with price gains.

Market effects

Sector

Health‑care consumer products sector may see modest lift from Perrigo's earnings beat.

Regional

U.S. market may see slight positive bias in consumer staples.

Global

Limited to U.S. investors; no broader global impact.

Counterpoint

What could challenge this read

Revenue missed estimates; a cautious trader may wait for guidance clarity before buying.

Key entities

  • Company
    Perrigo

    Consumer health products manufacturer (NYSE: PRGO).

Read at source← All news

StoryPerrigo reports Q3 loss, updates outlook and announces Infant Formula divestiture

Also covered by

6 outlets

Related articles

NOV 4
$PRGOMed

Perrigo 2026: Revenue $988.6M, EPS ($0.2) — 10-Q Summary

Perrigo reported 2026 nine-month net sales of $988.6M, down 5.2% YoY, and a net loss of $27.5M, compared to a net income of $7.5M in the prior year. Diluted loss per share was $0.2, versus earnings of $0.05. The decline was attributed to soft consumer demand, lower retailer inventories, and the sale of the Dermacosmetics business. Perrigo plans to sell its Infant Formula business for up to $175M and expects $80M-$100M in annual savings from a two-year efficiency program.

tradingview.com1 min
NOV 4
$PRGOHighAI 8/10

Perrigo Q3 2026 slides show sequential gains amid portfolio shift

Perrigo (NYSE:PRGO) reported Q3 2026 earnings with adjusted EPS of $0.60, beating estimates, while revenue of $989M missed expectations. The stock rose 4.62% to $16.43. Despite year-over-year declines, sequential improvements were noted in sales and margins. The company announced a divestiture of its Infant Formula business for $40M upfront and up to $135M in milestones, part of its strategic transformation.

investing.com2 min
NOV 4
$PRGOHigh

Perrigo Company Slips To Loss In Q3

Perrigo Company reported Q3 net sales of $989M, down from $1.04B last year. It posted a loss of $14.3M, or $0.10 per share, compared to a profit of $12.7M, or $0.09 per share, in the prior year. Adjusted earnings fell to $0.60 per share from $0.80. The company expects fiscal 2026 adjusted earnings of $2.25 to $2.45 per share. Pre-market, PRGO shares were up 1.02% at $15.84.

rttnews.com1 min
NOV 4
$PRGOMedAI 8/10

Perrigo beats earnings but misses on revenue

Perrigo (PRGO) reported Q3 earnings of $0.60 per share, beating estimates by $0.05, but revenue of $989M missed expectations and fell 5.2% YoY. Full-year 2026 EPS guidance was raised to $2.15-$2.35, above consensus. The company plans to sell its Infant Formula business for up to $175M, expecting an impairment loss of $275M-$375M in Q4. Shares rose 0.89% in pre-market trading.

investing.com1 min
NOV 4
$PRGOMed

Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations

PERRIGO Co plc (PRGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations • Execution of Three-S plan driving sequential improvement in operating results and market share gains across U.S. Store Brand OTC and key European brands • Infant Formula divestiture exp

SEC EDGAR 8-K3 min
NOV 4
$PRGOMedAI 8/10

Perrigo: Q3 Earnings Snapshot

Perrigo (PRGO) reported a Q3 loss of $27.5M, or 20 cents per share, but adjusted earnings of 60 cents beat estimates. Revenue of $988.6M missed expectations. The company forecasts full-year earnings of $2.25-$2.45 per share.

finance.yahoo.com1 min